title: Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Kolde
authors.forename: J Marcus
authors.initials: JM
authors.lastname: Muche
authors.forename: Peter
authors.initials: P
authors.lastname: Schulze
authors.forename: Peter
authors.initials: P
authors.lastname: Fischer
authors.forename: Jürgen
authors.initials: J
authors.lastname: Lichey
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007871:Leg Ulcer / Q000473:pathology; D008297:Male; D009335:Necrobiosis Lipoidica / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab